Retinal vein occlusion disease and platelet activation: Will antiplatelet therapy be a promising therapeutic strategy for patients with retinal vein occlusion disease in the future?

Thrombosis and Haemostasis

Volumn 97, Issue 2, 2007, Pages 169-170

  Fateh Moghadam, Suzanne ^a   Gawaz, Meinrad ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; BERABROST; PROSTACYCLIN DERIVATIVE; PROTEIN C; PROTEIN S; PROTHROMBIN; TICLOPIDINE; UNCLASSIFIED DRUG; COLLAGEN;

ARTERY THROMBOSIS; CENTRAL RETINA VEIN OCCLUSION; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; PATHOGENESIS; PATHOLOGICAL ANATOMY; PREVALENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RETINA BLOOD VESSEL; RETINA VEIN OCCLUSION; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOSIS; VEIN THROMBOSIS; BLOOD; BLOOD CLOTTING PARAMETERS; DRUG EFFECT; METABOLISM; SIGNAL TRANSDUCTION; THROMBOCYTE;

BLOOD PLATELETS; COLLAGEN; HUMANS; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PLATELET FUNCTION TESTS; RETINAL VEIN OCCLUSION; SIGNAL TRANSDUCTION;

EID: 33947496364     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH07-01-0007     Document Type: Editorial

References (13)

1. Shahid H, Hossain P, Amoaku WM. The management of retinal vein occlusion: is interventional ophathalmology the way forward? Br J Ophtalmol 2006; 90: 627-639.
2. Cheru KC, Zegans ME. Ophtalmology Review Manual. Philadelphia, Lippincott Williams & Wilkins, 2000; 132-146.
3. Prisco D, Marcucci R. Retinal vein thrombosis: risk factors, pathogenesis and therapeutic approach. Pathophysiol Haemost Thromb 2002; 32: 308-311.
4. Vannas S, Tarkkanen A. Retinal vein occlusion and glaucoma: tonographic study of the incidence of glaucoma and of its prognostic significance. Br J Ophtalmol 1960; 44: 583-589.
5. Janssen MC, den Heijer M, Cruysberg JR, et al. Retinal vein occlusion: a form of venous thrombosis or a complication of atherosclerosis? Thromb Haemost 2005; 93: 1021-1026.
6. Vine AK. Hyperhomocyteinemia: a risk factor for central retinal vein occlusion. Am J Ophtalmol 2000; 129: 640-644.
7. Leoncini G, Bruzzese D, Signorello MG, et al. Platelet activation by collagen is increased in retinal vein occlusion. Thromb Haemost 2007; 97: 218-227.
8. Watson PG, Gordon JL, Kok D, et al. Platelet aggregation study in ischemic retinal vascular disease. Trans Ophtalmol Soc UK 1971; 91: 223-230.
9. Priluck IA. Impending central venal occlusion associated with increased platelet aggregability. Ann Ophtalmol 1979; 11: 79-84.
10. Houtsmuller AJ, Vermeulen JACM, Klompe M, et al. The influence of ticlopidine on the natural course of retinal venal occlusion. Agents Actions Suppl 1984; 15: 219-229.
11. Walsh PN, Goldberg RE, Tax RL, et al. Platelet coagulant activities and retinal vein thrombosis. Thromb Haemost 1977; 38: 399-406.
12. Hayreh SS. Management of central vein occlusion. Ophtalmologica 2003; 217: 167-188.
13. Yamamoto T, Kamei M, Yokoi N, et al. Comparative effect of antiplatelet therapy in retinal vein occlusion evaluated by the particle-counting method using light scattering. Am J Ophtalmol 2004; 138: 809-817.